-
Mashup Score: 0GSK still riding vaccine sales wave, pushing 2024 forecasts higher - 14 hour(s) ago
GSK’s vaccines portfolio is front and center as it kicks off 2024. The UK pharma made £7.36 billion ($9.18 billion) in the first three months of the year, with its vaccine products contributing £2.27 billion ($2.83 billion). Its shingles vaccine Shingrix drew £945 million ($1.2 billion) and its RSV product
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Real Chemistry debuts a one-stop dashboard for all things GLP-1 - 15 hour(s) ago
Real Chemistry plans to harness the “Wild West” of GLP-1 social media and reams of competitive data in the drug category with a new platform called IRIS. An all-in-one dashboard sits at the center of the service with real-time data that include clinical trial tracking, script and claims information, consumer
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its long-standing peptide discovery deal with PeptiDream to bolster their work on peptides for conjugation with radionuclide compounds. The Japanese biotech, which has a long list of drug development partners, will get
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Merck bolstered its pneumococcal vaccine data on Monday, suggesting its experimental 21-valent shot V116 offers broader protection for older adults than Pfizer’s market-leading 20-valent Prevnar 20. An approval in the coming weeks would stoke Merck’s yearslong rivalry with Pfizer, whose Prevnar 20 was first approved in 2021, a mere month before
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 18
Japanese drugmaker Ono Pharmaceutical is acquiring cancer-focused biotech Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday morning. The deal will see Ono acquire all outstanding Deciphera stock at a price of $25.60 per share, representing about a 75% premium over its Friday closing price of $14.65. It’s expected to
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2GSK accuses Pfizer and BioNTech of mRNA patent infringement - 6 day(s) ago
GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners. In a lawsuit filed in federal court in Delaware Thursday, the UK pharma claimed Pfizer and BioNTech benefited from mRNA research conducted more than a decade
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 1
Cidara Therapeutics announced several sweeping moves on Wednesday afternoon to bring an influenza drug back in-house and raise money from investors to back the program. The San Diego biotech said it will reacquire the flu drug candidate, CD388, from Johnson & Johnson after a deal with the drug giant three
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 2
The
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters Thursday morning. Hudson also said that the French pharma is not expecting a significant impact from the US legislation targeting Chinese service providers given the
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
The FDA’s Center for Biologics Evaluation and Research is planning to release some crucial guidance soon for CRISPR and gene therapy developers on platform technologies, accelerated approvals for rare diseases, and potentially in the
Source: endpts.comCategories: General Medicine News, Rare DiseaseTweet
“The UK pharma said its non-Covid vaccine sales grew 22% in the first three months of the year to £2.27 billion” https://t.co/71BmUpH8Z3